THE IMPORTANCE OF GENOTYPIC AND IMMUNOPHENOTYPIC CHARACTERISTICS IN THE PATHOGENESIS AND TREATMENT OF CHRONIC HCV-INFECTION
- Authors: Nabieva U.P.1, Ismailova A.A.1, Adylov D.G.1
-
Affiliations:
- Republican Scientific Center of Immunology of the Ministry of Health of the Republic of Uzbekistan
- Issue: Vol 20, No 3 (2017)
- Pages: 435-439
- Section: Articles
- URL: https://bakhtiniada.ru/1028-7221/article/view/119651
- ID: 119651
Cite item
Full Text
Abstract
About the authors
U. P. Nabieva
Republican Scientific Center of Immunology of the Ministry of Health of the Republic of Uzbekistan
Author for correspondence.
Email: noemail@neicon.ru
Russian Federation
A. A. Ismailova
Republican Scientific Center of Immunology of the Ministry of Health of the Republic of Uzbekistan
Email: noemail@neicon.ru
Russian Federation
D. G. Adylov
Republican Scientific Center of Immunology of the Ministry of Health of the Republic of Uzbekistan
Email: noemail@neicon.ru
Russian Federation
References
- Ивашкин В. Т., Мамаев С. Н., Лукина Е. А. Особенности иммунного статуса у больных хроническим вирусным гепатитом С // Рос.журнал гастроэн., гепатол., колопроктол.- 2001.- № 3.-С. 24-29.
- Мицура В. М., Воропаев Е. В., Осипкина О. В., Жаворонок С. В. Полиморфизм генов интерлей-кина-28В и клиническое значение его выявления у пациентов с хроническим вирусным гепатитов С.// Лабораторная диагностика. -2012. -№ 2. -С. 86-97.
- Davis G. L. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis С.// Hepatology.- 2003.-№ 38.- P. 645-652.
- Fellay D. Ge, J. et al. Genetic variation in IL28B predicts hepatitis С treatment-induced viral clearance. // J. Nature.- 2009.- Vol. 461.- P. 399-401.
- Fried M. W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis С virus infection / // N Engl J Med.- 2002.- Vol. 347.- P. 975-982.
- Ge D., Fellay J., Thompson AJ. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17; 461(7262): 399-401.
- Grebely J. et al. Potential role for lnterleukin-28B genotype in treatment decision-making in recent hepatitis С virus infection. // Hepatology - 2010.-Vol. 52.- P. 1216-1224.
- Lotrich F. E. et al. IL28B polymorphism is associated with both side effects and clearance of hepatitis С during interferon- alpha therapy.//Journal of Interferon & Cytokine Research.- 2011.- Vol. 31.-№ 3.- P. 331-336. Marc G. G. Diagnosis, management and treatment of hepatitis C. // Hepatology.- 2009.- Vol. 49.- P. 1335-1374.
- Ray Kim.W. Global epidemiology and burden of hepatitis C. Microbes.Infect. 4, 1219-1225 (2002).
- Rauch A. Genetic Variation in IL28B Is Associated With Chronic Hepatitis С and Treatment Failure: A Genome-Wide Association Study.// Gastroenterology.- 2010.- Vol. 138.- P. 1338-1345.
- Tanaka Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis С.// Nat Genet.- 2009.- Vol. 41.- P. 1105-1109.
- Thompson AJ. et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis С virus / // Gastroenterology.-2010.- Vol. 139.- P. 120-129.
Supplementary files
